FEATURED
Lilly Doubles Down on Nimbus in $1.3B Oral Obesity Pact
Nimbus Therapeutics has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to
DEALS
Sanofi Strengthens Vaccine Portfolio with $2.2B Dynavax Acquisition
Sanofi has announced it has agreed to acquire Dynavax Technologies Corporation, a publicly traded vaccines company, in a move that
PRESS RELEASES
Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision
Striatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
EDITOR’S PICKS
Alpha-Synuclein Aggregation: A Key Target in the Battle Against Parkinson’s Disease
Parkinson’s disease (PD) is a progressive neurodegenerative condition impacting millions globally. While a blend of genetic, environmental, and ageing factors
RESOURCES
A Game-Changer in Predicting Drug-Induced Gastrointestinal Toxicity
CacoReady, a Useful Cell Model to Predict Drug-Induced Gastrointestinal Toxicity A ReadyCell .pdf Case Study – Author: Marta Olle Monge,
MANUFACTURING PROJECTS
Eli Lilly to Invest $6 Billion in New API Manufacturing Facility in Alabama, USA
The new Huntsville, Alabama site will produce small molecule and peptide medicines, including oral GLP-1 orforglipron Eli Lilly and Company
CLINICAL TRIALS
Lilly’s Jaypirca Outperforms Imbruvica in CLL Head-to-Head Phase 3 Trial
Eli Lilly’s Jaypirca (pirtobrutinib), the first and only FDA-approved non-covalent (reversible) BTK inhibitor, has met its primary endpoint in the
REGULATORY
FDA Approves Novo’s Wegovy® Pill as First Oral GLP-1 Weight Loss Therapy
Novo Nordisk A/S has announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral
SELECTED PRODUCTS
Device for Visual Acuity Testing of Laboratory Animals
The cutting-edge AcuiSee device for visual acuity testing of laboratory animals stands out as a breakthrough in the realm of
